Abstract: Objective： To investigate the clinical efficacy and adverse reactions of paclitaxel plus oxaliplatin in the treatment of recurrent or advanced cervical cancer. Methods：32 patients of recurrent or advanced cervical cancer were given the chemotherapy of paclitaxel plus oxaliplatin ：the dose of paclitaxel was 150 mg/m2 intravenous infusion ≥3 h in the first day，and the dose of oxaliplatin was 130 mg/m2 intravenous infusion ≥ 2 h in the second day，the course was repeated every 3 weeks，the evaluations of the short term or long term and adverse reactions were evaluated after 2 cycles treatment. Results：All patients can participate in the evaluation of curative effect，and the total effective rate was 25%. The median progression free survival and median overall survival were 21.2 weeks and 52.1 weeks respectively. The main adverse reactions were toxicities and myelosuppression，non-hematologic adverse reaction was mild. Conclusions：Paclitaxel plus oxaliplatin has quite valid curative effect on the treatment of recurrent or advanced cervical cancer patients，the adverse reactions can be tolerated，which was worthy for the further clinical research.

Key words: Paclitaxel, Organoplatinum compounds, Uterine cervical neoplasms, Neoplasm recurrence, local, Drug therapy